SCHEMBL7654114

SCHEMBL7654114

Cc1cc(C(=O)Nc2ccc(Cl)cc2O)c(Br)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 1/20 0.51
F10 P00742 2/20 0.49
F12 P00748 1/20 0.49
KCNMA1 Q12791 7/20 0.47
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
POLB P06746 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
NPY1R P25929 1/20 0.44
HTT P42858 1/20 0.44
NPY2R P49146 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
HPGD P15428 1/20 0.43
TMPRSS4 Q9NRS4 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6998631 0.90 KCNMA1 (0.61) F12KCNMA1NPC1RAB9APOLB
SCHEMBL6995125 0.86 RAB9A (0.53) CXCR2KCNMA1NPC1RAB9ALMNA
SCHEMBL7661723 0.84 HDAC1 (0.43) KCNMA1NPC1RAB9APOLBKDM4E
SCHEMBL6997403 0.82 NPC1 (0.55) F12KCNMA1NPC1RAB9APOLB
SCHEMBL7665120 0.82 MAPT (0.50) F10NPC1RAB9APOLBLMNA
SCHEMBL7660313 0.80 KCNMA1 (0.60) CXCR2KCNMA1NPC1RAB9APOLB
SCHEMBL6991334 0.78 KCNMA1 (0.57) KCNMA1NPC1RAB9ALMNAMAPT
SCHEMBL6996991 0.76 KCNMA1 (0.52) KCNMA1NPC1RAB9APOLBKDM4E
SCHEMBL17224032 0.76 RAB9A (0.53) CXCR2F10KCNMA1NPC1RAB9A
SCHEMBL7666549 0.75 MAPT (0.49) KCNMA1NPC1RAB9APOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
CN-1268949-A Fused thiophene compounds and medical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2000-10-04 CN disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT CXCR2 2700/4885F10 1919/4885F12 1351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.